| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 05/10/2002 | WO2002036627A2 Interferons, uses and compositions related thereto |
| 05/10/2002 | WO2002036619A1 A new polypeptide-human glycoprotein 42 and the polynucleotide encoding it |
| 05/10/2002 | WO2002036611A2 Immunomodulatory peptides derived from heat shock proteins and uses thereof |
| 05/10/2002 | WO2002036605A2 Estrone-derivatives having cytoprotective activity |
| 05/10/2002 | WO2002036590A1 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives |
| 05/10/2002 | WO2002036589A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents |
| 05/10/2002 | WO2002036573A2 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
| 05/10/2002 | WO2002036571A1 (7-(3-carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine |
| 05/10/2002 | WO2002036547A1 Cyclopropanecarboxylic acid amide compounds and medicinal use thereof |
| 05/10/2002 | WO2002036151A2 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies |
| 05/10/2002 | WO2002036149A2 Methods for obtaining inhibitors of t-cell membrane protein (tirc7) ligand binding and uses thereof |
| 05/10/2002 | WO2002036148A2 Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death |
| 05/10/2002 | WO2002036110A2 Oral self-emulsifying formulations of pyranone protease inhibitors |
| 05/10/2002 | WO2002016381A3 Composition and method for inhibiting platelet aggregation |
| 05/10/2002 | WO2002013857A8 A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof |
| 05/10/2002 | WO2001096525A3 A novel polypeptide, a pogo conversion unit 18 and the polynucleotide encoding the polypeptide |
| 05/10/2002 | WO2001092337A3 Soluble ctla4 mutant molecules and uses thereof |
| 05/10/2002 | WO2001090316A3 Human circulating dendritic cell compositions and methods |
| 05/10/2002 | WO2001088116A3 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods |
| 05/10/2002 | WO2001085185A3 Treatment of il-10 deficiencies |
| 05/10/2002 | WO2001083750A3 Dendritic cell co-stimulator molecules |
| 05/10/2002 | WO2001079469A3 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
| 05/10/2002 | WO2001079288A3 Cytokine uses; compositions; methods |
| 05/10/2002 | WO2001076639A3 Chemically-modified myelopoietin conjugates |
| 05/10/2002 | WO2001068697A3 Methods and compositions for immunoregulation |
| 05/10/2002 | WO2001068677A3 Derivatives of breast canacer antigen her-2 for therapeutical use |
| 05/10/2002 | WO2001068034B1 1, 2, 4-triazoloribonucleoside prodrugs and their administration to treat viral disease conditions |
| 05/10/2002 | WO2001066742A3 G-protein coupled receptors |
| 05/10/2002 | WO2001066594A3 Human protein kinases and protein kinase-like enzymes |
| 05/10/2002 | WO2001066122A3 Herbal remedies for treating allergies and asthma |
| 05/10/2002 | WO2001064879A3 G-proteins coupled receptor related polypeptides |
| 05/10/2002 | WO2001064214A3 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| 05/10/2002 | WO2001047963A3 Inhibitors of complement activation, their preparation and use |
| 05/10/2002 | WO2001045745A3 A reversible linkage technology for controlled conjugation |
| 05/10/2002 | WO2001042472A3 DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE |
| 05/10/2002 | WO2001036638A3 Polypeptides and nucleic acids encoding same |
| 05/10/2002 | WO2001036487A3 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/10/2002 | WO2001036467A3 Mammalian receptor proteins; related reagents and methods |
| 05/10/2002 | WO2001036432A3 18 human secreted proteins |
| 05/10/2002 | WO2001035990A3 Method for enhancing t cell reactivity toward tumour antigens |
| 05/10/2002 | WO2001032709A3 Polypeptides with non-natural primary signalling motifs |
| 05/10/2002 | WO2001032650A3 Alkaline salts of n-(6-alkyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinesulfone)-n'-isonicotinoylhydrazide, possess for their preparation, and pharmaceutical composition based on these salts |
| 05/10/2002 | WO2001031007A9 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/10/2002 | WO2001028580A3 Modulation of angiogenesis |
| 05/10/2002 | WO2001027146A9 Chemokine receptor |
| 05/10/2002 | WO2001024827A3 INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 05/10/2002 | WO2001023386A3 Benzodiazepin derivatives, the production and use thereof |
| 05/10/2002 | WO2001001976A3 Composition comprising an extract of perna canaliculus, methylsulfonylmethane and glucosamine |
| 05/10/2002 | WO2000073507A3 Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders |
| 05/10/2002 | WO2000073349A9 Dr4 antibodies and uses thereof |
| 05/10/2002 | WO2000067761A8 Compositions and methods for identifying antigens which elicit an immune response |
| 05/10/2002 | WO2000058339A3 50 human secreted proteins |
| 05/10/2002 | WO2000054802A3 Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization |
| 05/10/2002 | WO2000050639A3 Gene sequence variations with utility in determining the treatment of disease |
| 05/10/2002 | CA2427952A1 Dna expression vectors |
| 05/10/2002 | CA2427850A1 Interferons, uses and compositions related thereto |
| 05/10/2002 | CA2427613A1 (7-(3-carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine |
| 05/10/2002 | CA2427589A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents |
| 05/10/2002 | CA2427572A1 Immunomodulatory peptides derived from heat shock proteins and uses thereof |
| 05/10/2002 | CA2427533A1 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies |
| 05/10/2002 | CA2427518A1 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 05/10/2002 | CA2427394A1 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives |
| 05/10/2002 | CA2427257A1 Expression vectors able to elicit improved immune response and methods of using same |
| 05/10/2002 | CA2425583A1 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof |
| 05/10/2002 | CA2424932A1 Cd36 as a heat shock protein receptor and uses thereof |
| 05/10/2002 | CA2395324A1 Expression potentiator for protein synthesis regulatory gene |
| 05/09/2002 | WO2002036153A1 Expression potentiator for protein synthesis regulatory gene |
| 05/09/2002 | US20020055632 Such as (3R,5S)-1-pyrimidin-2-yl-5-(2,4,5-trifluoro-benzyloxymethyl)-pyrrolidine-3 -thiol trifluoro-acetate useful as inhibitors of metalloproteases for treating diseases associated with vasoconstriction |
| 05/09/2002 | US20020055615 Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology |
| 05/09/2002 | US20020055543 Inhibit phosphodiesterase type IV or inhibit the production of tumor necrosis factor; useful in treating diseases including asthma, arthritis, and sepsis. |
| 05/09/2002 | US20020055538 Aspirin-triggered lipid mediators |
| 05/09/2002 | US20020055526 Modulators of SKCa, IKCa and BKCa channels. |
| 05/09/2002 | US20020055518 Polyoxyethylated hydroxyesters of rapamycin useful in inducing immunosuppression and in the treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease. |
| 05/09/2002 | US20020055516 Nitrogen-containing heterocyclic compounds and medicaments containing the compounds |
| 05/09/2002 | US20020055515 Contacting stimulated cells with a candidate compound which is an inhibitor of ATP binding to a P2Y- purinoceptor; and assaying said cells for release of one or more mediators. |
| 05/09/2002 | US20020055513 7-oxo-pyridopyrimidines (II) |
| 05/09/2002 | US20020055507 Ureas and thioureas inhibit production of cytokines |
| 05/09/2002 | US20020055492 Recognizes the extracellular domain of the human IFN-R and which has neutralizing capacity against the biological properties of human type I-IFN. |
| 05/09/2002 | US20020055477 Immunomodulatory formulations and methods for use thereof |
| 05/09/2002 | US20020055476 RAMPs are small proteins that transport calcitonin-receptor-like proteins to the plasma membrane; drug screening |
| 05/09/2002 | US20020055475 Cytidylyl(3'-->5')guanosine ammonium salt (CpG); reducing the immunostimulatory effect for antisense applications |
| 05/09/2002 | US20020055456 Therapeutic methods that target fractalkine or CX3CR1 |
| 05/09/2002 | US20020055142 Major intrinsic protein (MIP)-like polynucleotides, polypeptides, and antibodies |
| 05/09/2002 | US20020055122 Administering to the recipient mammal for promoting acceptance of graft, an inhibitor of the CD40/ ligand- CD40 costimulatory interaction; introducing into the recipient mammal, hematopoietic stem cells and implanting the graft |
| 05/09/2002 | US20020054880 Suppressing inflammatory response in mammal by the administration of lectin derived carbohydrate binding peptide capable of binding terminally linked alpha-sialic acid derivative |
| 05/09/2002 | US20020054879 Reacting protein with polysaccharide to produce mixture including protein-polysaccharide conjugate and free protein |
| 05/09/2002 | US20020054878 Anti-IgE antibodies |
| 05/09/2002 | US20020054875 Administering to a patient of inflammatory arthritis a therapeutically effective amount of an antagonist of CX3CR1 function or fractalkine fucntion(a chemokine protein or antibody or newly discovered T-cell, a cell adhesion protein) |
| 05/09/2002 | US20020054873 Attenuating the tumor cells, introducing a nucleic acid molecule which encodes and OX-40 receptor binding agent which is expressed on the surface of tumor cells, administering the above preperation |
| 05/09/2002 | US20020054868 Bacterial strain, processes plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 05/09/2002 | US20020054867 A probiotic formulation of Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799); containing at least one volatile fraction (VF) of a plant extract |
| 05/09/2002 | US20020054866 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 05/08/2002 | EP1203819A2 Anti-inflammatory vectors |
| 05/08/2002 | EP1203817A2 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 05/08/2002 | EP1203766A2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 05/08/2002 | EP1203587A1 A medicament and method for the production thereof |
| 05/08/2002 | EP1203239A2 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 05/08/2002 | EP1203092A1 Antisense modulation of map kinase kinase 6 expression |
| 05/08/2002 | EP1203081A2 Human intracellular signaling molecules |
| 05/08/2002 | EP1203024A1 Human tumor necrosis factor receptors tr13 and tr14 |